SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    ACCF/AHA Task Force on Practice Guidelines. Methodologies and Policies from the ACCF/AHA Task Force on Practice Guideline. Available at http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf and http://circ.ahajournals.org/site/manual/index.xhtml. Accessed July 1, 2011.
  • 2
    Hirsch AT, Haskal ZJ, Hertzer NR, etal. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary: a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardio vascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Circulation. 2006; 113: 1474547.
  • 3
    Norgren L, Hiatt WR, Dormandy JA, etal. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007; 33 Suppl 1: S175.
  • 4
    Hirsch AT, Haskal ZJ, Hertzer NR, etal. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/ Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Circulation. 2006; 113: e463654.
  • 5
    Wheatley K, Ives N, Gray R, etal. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 2009; 361: 195362.
  • 6
    Cooper CJ, Murphy TP, Matsumoto A, etal. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J. 2006; 152: 5966.
  • 7
    Alhadad A, Mattiasson I, Ivancev K, etal. Revascularisation of renal artery stenosis caused by fibromuscular dysplasia: effects on blood pressure during 7-year follow-up are influenced by duration of hypertension and branch artery stenosis. J Hum Hypertens. 2005; 19: 7617.
  • 8
    Modrall JG, Rosero EB, Smith ST, etal. Operative mortality for renal artery bypass in the United States: results from the National Inpatient Sample. J Vasc Surg. 2008; 48: 31722.
  • 9
    Criqui MH, Denenberg JO, Bird CE, etal. The correlation between symptoms and non-invasive test results in patients referred for peripheral arterial disease testing. Vasc Med. 1996; 1: 6571.
  • 10
    Hirsch AT, Criqui MH, Treat-Jacobson D, etal. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001; 286: 131724.
  • 11
    Diehm C, Allenberg JR, Pittrow D, etal. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009; 120: 205361.
  • 12
    Fowkes FG. The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys. Int J Epidemiol. 1988; 17: 24854.
  • 13
    Feigelson HS, Criqui MH, Fronek A, etal. Screening for peripheral arterial disease: the sensitivity, specificity, and predictive value of non-invasive tests in a defined population. Am J Epidemiol. 1994; 140: 52634.
  • 14
    Nassoura ZE, Ivatury RR, Simon RJ, etal. A reassessment of Doppler pressure indices in the detection of arterial lesions in proximity penetrating injuries of extremities: a prospective study. Am J Emerg Med. 1996; 14: 1516.
  • 15
    Carter SA. Clinical measurement of systolic pressures in limbs with arterial occlusive disease. JAMA. 1969; 207: 186974.
  • 16
    Carter SA, Tate RB. Value of toe pulse waves in addition tosystolic pressures in the assessment of the severity of peripheral arterial disease and critical limb ischemia. J Vasc Surg. 1996; 24: 25865.
  • 17
    Carter SA, Tate RB. The value of toe pulse waves in determination of risks for limb amputation and death in patients with peripheral arterial disease and skin ulcers or gangrene. J Vasc Surg. 2001; 33: 70814.
  • 18
    Brooks B, Dean R, Patel S, etal. TBI or not TBI: that is the question: is it better to measure toe pressure than ankle pressure in diabetic patients? Diabet Med. 2001; 18: 52832.
  • 19
    Ramsey DE, Manke DA, Sumner DS. Toe blood pressure: a valuable adjunct to ankle pressure measurement for assessing peripheral arterial disease. J Cardiovasc Surg (Torino). 1983; 24: 438.
  • 20
    Belcaro G, Nicolaides AN, Bull ML, etal. The value of segmental pressure measurement in the assessment of peripheral vascular disease. Int Angiol. 1986; 5: 712.
  • 21
    Gundersen J. Segmental measurements of systolic blood pressure in the extremities including the thumb and the great toe. Acta Chir Scand Suppl. 1972; 426: 190.
  • 22
    Johnston KW, Hosang MY, Andrews DF. Reproducibility of noninvasive vascular laboratory measurements of the peripheral circulation. J Vasc Surg. 1987; 6: 14751.
  • 23
    Kupinski A. Segmental pressure measurement and plethysmography. J Vasc Technol. 2002; 1: 328.
  • 24
    Fowkes FG, Murray GD, Butcher I, etal. Ankle brachial indexcombined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008; 300: 197208.
  • 25
    Nides MA, Rakos RF, Gonzales D, etal. Predictors of initial smoking cessation and relapse through the first 2 years of the Lung Health Study. J Consult Clin Psychol. 1995; 63: 609.
  • 26
    Mohiuddin SM, Mooss AN, Hunter CB, etal. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest. 2007; 131: 44652.
  • 27
    Lancaster T, Stead LF. Mecamylamine (a nicotine antagonist) for smoking cessation. Cochrane Database Syst Rev. 2000; CD001009.
  • 28
    Rothemich SF, Woolf SH, Johnson RE, etal. Effect on cessation counseling of documenting smoking status as a routine vital sign: an ACORN study. Ann Fam Med. 2008; 6: 608.
  • 29
    Hennrikus D, Joseph A, Lando H, etal. Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial. JACC. 2010; 25: 210512.
  • 30
    Gonzales D, Rennard SI, Nides M, etal. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006; 296: 4755.
  • 31
    Jorenby DE, Hays JT, Rigotti NA, etal. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006; 296: 5663.
  • 32
    Nides M, Oncken C, Gonzales D, etal. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006; 166: 15618.
  • 33
    Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999; 340: 68591.
  • 34
    Faulkner KW, House AK, Castleden WM. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med J Aust. 1983; 1: 2179.
  • 35
    Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication: effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand. 1987; 221: 25360.
  • 36
    Lassila R, Lepantalo M. Cigarette smoking and the outcome after lower limb arterial surgery. Acta Chir Scand. 1988; 154: 63540.
  • 37
    Quick CR, Cotton LT. The measured effect of stopping smoking on intermittent claudication. Br J Surg. 1982; 69 Suppl: S246.
  • 38
    Gardner AW. The effect of cigarette smoking on exercise capacity in patients with intermittent claudication. Vasc Med. 1996; 1: 1816.
  • 39
    Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med. 1995; 155: 193341.
  • 40
    West R, Baker CL, Cappelleri JC, etal. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl). 2008; 197: 3717.
  • 41
    Knight C, Howard P, Baker CL, etal. The cost-effectiveness of an extended course (12 + 12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model. Value Health. 2010; 13: 20914.
  • 42
    Olin JW. Thromboangiitis obliterans (Buerger's disease). N Engl J Med. 2000; 343: 8649.
  • 43
    CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996; 348: 132939.
  • 44
    Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [published correction appears in BMJ. 2002;324:141]. BMJ. 2002; 324: 7186.
  • 45
    Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med. 2007; 261: 27684.
  • 46
    Belch J, MacCuish A, Campbell I, etal. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008; 337: a1840.
  • 47
    Fowkes FG, Price JF, Stewart MC, etal. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010; 303: 8418.
  • 48
    Bhatt DL, Fox KA, Hacke W, etal. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354: 170617.
  • 49
    Cacoub PP, Bhatt DL, Steg PG, etal. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009; 30: 192201.
  • 50
    Anand S, Yusuf S, Xie C, etal. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007; 357: 21727.
  • 51
    Berger JS, Krantz MJ, Kittelson JM, etal. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009; 301: 190919.
  • 52
    Bhatt DL, Flather MD, Hacke W, etal. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007; 49: 19828.
  • 53
    Bernstein EF, Rhodes GA, Stuart SH, etal. Toe pulse reappearance time in prediction of aortofemoral bypass success. Ann Surg. 1981; 193: 2015.
  • 54
    Bradbury AW, Adam DJ, Bell J, etal. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: an intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. J Vasc Surg. 2010; 51: 5S17S.
  • 55
    Adam DJ, Beard JD, Cleveland T, etal. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005; 366: 192534.
  • 56
    Greenhalgh RM, Brown LC, Powell JT, etal. Endovascular versus open repair of abdominal aortic aneurysm. N Engl J Med. 2010; 362: 186371.
  • 57
    Blankensteijn JD, de Jong SE, Prinssen M, etal. Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms. N Engl J Med. 2005; 352: 2398405.
  • 58
    De Bruin JL, Baas AF, Buth J, etal. Long-term outcome of open or endovascular repair of abdominal aortic aneurysm. N Engl J Med. 2010; 362: 18819.
  • 59
    Greenhalgh RM, Brown LC, Powell JT, etal. Endovascular repair of aortic aneurysm in patients physically ineligible for open repair. N Engl J Med. 2010; 362: 187280.
  • 60
    Lederle FA, Freischlag JA, Kyriakides TC, etal. Outcomes following endovascular vs open repair of abdominal aortic aneurysm: a randomized trial. JAMA. 2009; 302: 153542.
  • 61
    Brown LC, Epstein D, Manca A, etal. The UK Endovascular Aneurysm Repair (EVAR) trials: design, methodology and progress. Eur J Vasc Endovasc Surg. 2004; 27: 37281.
  • 62
    Schanzer A, Hevelone N, Owens CD, etal. Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. J Vasc Surg. 2008; 47: 77481.
  • 63
    Conte MS, Bandyk DF, Clowes AW, etal. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg. 2006; 43: 74251.
  • 64
    Diehm C, Schuster A, Allenberg JR, etal. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis. 2004; 172: 95105.
  • 65
    Hennrikus D, Joseph AM, Lando HA, etal. Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial. J Am Coll Cardiol. 2010; 56: 210512.
  • 66
    Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2004; 148: 2638.